← All trials
NCT05698186
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 15, 2023
- Primary completion
- May 15, 2027
- Completion date
- May 15, 2027
- First posted
- Jan 26, 2023
- Last posted
- Jan 26, 2023
- Enrollment
- 320
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Institut de Cancerologie Strasbourg EuropeLead sponsor
- Institut de Cancerologie Strasbourg EuropeStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.